Pulmonx Corp

For the period ended Jun 30, 2024. Filed Aug 2, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 2, 2024

LUNG$2.800.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Operations and Comprehensive Loss

(in thousands, except share and per share amounts)

	Three Months Ended June 30,		Six Months Ended June 30,
	2024	2023	2024	2023
Revenue	$20,783	$17,194	$39,637	$31,729
Cost of goods sold	5,476	4,460	10,252	8,406
Gross profit	15,307	12,734	29,385	23,323
Operating expenses
Research and development	5,615	5,710	9,825	9,963
Selling, general and administrative	25,314	23,463	49,718	46,199
Total operating expenses	30,929	29,173	59,543	56,162
Loss from operations	(15,622)	(16,439)	(30,158)	(32,839)
Interest income	1,306	1,410	2,747	2,537
Interest expense	(891)	(864)	(1,774)	(1,435)
Other (expense) income, net	(35)	(162)	380	(54)
Net loss before tax	(15,242)	(16,055)	(28,805)	(31,791)
Income tax expense	84	140	270	264
Net loss	(15,326)	(16,195)	(29,075)	(32,055)
Other comprehensive income (loss)
Currency translation adjustment	40	170	(509)	242
Change in unrealized (losses) gains on marketable securities	(30)	(34)	(158)	139
Total other comprehensive income (loss)	10	136	(667)	381
Comprehensive loss	$(15,316)	$(16,059)	$(29,742)	$(31,674)
Net loss per share attributable to common stockholders, basic and diluted	$(0.39)	$(0.43)	$(0.75)	$(0.85)
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted	38,943,066	37,818,256	38,789,548	37,696,001

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.